Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphatic Metastasis 1Gliosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 19Specimen Handling 19Biopsy 13Magnetic Resonance Spectroscopy 12Carboplatin 11Paclitaxel 10Pemetrexed 8Nivolumab 7Irinotecan 7Gemcitabine 7trastuzumab deruxtecan 6Fulvestrant 6Radiosurgery 5Leucovorin 5Fluorouracil 5Cisplatin 5Cetuximab 5Bevacizumab 5palbociclib 4durvalumab 4Taxes 4Oxaliplatin 4Letrozole 4Docetaxel 4ribociclib 3olaparib 3Trastuzumab 3Panitumumab 3Midazolam 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × peposertib × 30 days × Clear all
NCT05687136 2026-06-11

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
66 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡